Solenne Ousson

O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies

Bruno Permanne, Astrid Sand, Solenne Ousson et al. · ACS Chemical Neuroscience · 2022 · 72 citations · Full text

The Role of γ-Secretase Activating Protein (GSAP) and Imatinib in the Regulation of γ-Secretase Activity and Amyloid-β Generation

Ishrut Hussain, Julien Fabrègue, Laurence Anderes et al. · Journal of Biological Chemistry · 2012 · 47 citations · Full text

Generation and characterization of a rabbit monoclonal antibody site‐specific for tau O‐GlcNAcylated at serine 400

Andrew Cameron, Brandy Giacomozzi, John A. Joyce et al. · FEBS Letters · 2013 · 31 citations

Tau O-glcnacylation, Glycobiology, Immunology +18

O1‐12‐05: PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE O‐GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSY AND RELATED TAUOPATHIES

J. Michael Ryan, Anna Quattropani, Khalid Abd‐Elaziz et al. · Alzheimer s & Dementia · 2018 · 30 citations

Neurodegenerative Diseases, Medicinal Chemistry, Alzheimer's Disease +14

Substrate determinants in the C99 juxtamembrane domains differentially affect γ–secretase cleavage specificity and modulator pharmacology

Solenne Ousson, Arman Saric, Aurélie Baguet et al. · Journal of Neurochemistry · 2012 · 23 citations

Gsm Mechanism, Cleavage Specificity, Protein Secretion +16